Literature DB >> 29589280

Response to cyclosporine A and corticosteroids in adult patients with acquired pure red cell aplasia: serial experience at a single center.

Xuemei Wu1, Suli Wang1, Xingyu Lu1, Wenyi Shen1, Chun Qiao1, Yujie Wu1, Ruinan Lu1, Shuai Wang1, Jianfu Zhang1, Ming Hong1, Yu Zhu1, Jianyong Li1, Guangsheng He2.   

Abstract

To assess response to cyclosporine A, and/or corticosteroids, and possible factors influencing the response in adult patients with acquired pure red cell aplasia (PRCA). Clinical data from 42 cases were retrospectively analyzed. These patients received cyclosporine A (CsA), and/or corticosteroids (CS), or other immunosuppressive agents on becoming refractory and relapse. Thirty-nine patients were evaluated. Remission induction therapy included CsA (n = 16), CS (n = 13), CsA in combination with CS (n = 6), or other immunosuppressive agents (n = 4). Initial response rates were 75.0, 46.2, 66.7 and 75.0%, respectively (P = 0.456). Cumulative response rates in patients who received CsA, CS, CsA in combination with CS, or other immunosuppressive agents were 69.6% (16/23), 50.0% (7/14), 71.4% (5/7), 42.9% (6/14), respectively (P = 0.376). Cumulative rates of CR were 26.1% (6/23), 28.6% (4/14), 57.1% (4/7), 14.3% (2/14), respectively (P = 0.284). In 27 refractory and relapsed PRCA patients, 11 of 17 patients (64.7%) achieved remission by CsA and/or CS regimen, while three of ten patients (30.0%) responded to other immunosuppressive agents (P = 0.120). CsA and/or CS were effective in treating PRCA. For patients with relapse or refractory PRCA, there were no satisfactory treatments if CsA and/or CS failed or were not administered.

Entities:  

Keywords:  Corticosteroids; Cyclosporine A; Pure red cell aplasia

Mesh:

Substances:

Year:  2018        PMID: 29589280     DOI: 10.1007/s12185-018-2446-y

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  21 in total

1.  Successful treatment of pure red cell aplasia with rituximab in patients with chronic lymphocytic leukemia.

Authors:  Hassan Ghazal
Journal:  Blood       Date:  2002-02-01       Impact factor: 22.113

2.  Anti-CD20 monoclonal antibody for the treatment of severe, immune-mediated, pure red cell aplasia and hemolytic anemia.

Authors:  M Zecca; P De Stefano; B Nobili; F Locatelli
Journal:  Blood       Date:  2001-06-15       Impact factor: 22.113

Review 3.  Large granular lymphocyte leukemia.

Authors:  Lubomir Sokol; Thomas P Loughran
Journal:  Oncologist       Date:  2006-03

4.  Clinical analysis of 52 patients with granular lymphocyte proliferative disorder (GLPD) showed frequent anemia in indolent T-cell GLPD in Japan.

Authors:  Shimpei Kawahara; Makoto Sasaki; Yasushi Isobe; Jun Ando; Masaaki Noguchi; Michiaki Koike; Takao Hirano; Kazuo Oshimi; Koichi Sugimoto
Journal:  Eur J Haematol       Date:  2009-01-29       Impact factor: 2.997

5.  Long-term outcome of patients with acquired primary idiopathic pure red cell aplasia receiving cyclosporine A. A nationwide cohort study in Japan for the PRCA Collaborative Study Group.

Authors:  Ken-ichi Sawada; Makoto Hirokawa; Naohito Fujishima; Masanao Teramura; Masami Bessho; Kazuo Dan; Hisashi Tsurumi; Shinji Nakao; Akio Urabe; Mitsuhiro Omine; Keiya Ozawa
Journal:  Haematologica       Date:  2007-07-20       Impact factor: 9.941

6.  Successful treatment of refractory pure red cell aplasia associated with lymphoproliferative disorders with the anti-CD52 monoclonal antibody alemtuzumab (Campath-1H).

Authors:  Xiuqing Ru; Howard A Liebman
Journal:  Br J Haematol       Date:  2003-10       Impact factor: 6.998

7.  Pure red cell aplasia: association with large granular lymphocyte leukemia and the prognostic value of cytogenetic abnormalities.

Authors:  M Q Lacy; P J Kurtin; A Tefferi
Journal:  Blood       Date:  1996-04-01       Impact factor: 22.113

8.  Long-term responses and outcomes following immunosuppressive therapy in large granular lymphocyte leukemia-associated pure red cell aplasia: a Nationwide Cohort Study in Japan for the PRCA Collaborative Study Group.

Authors:  Naohito Fujishima; Ken-ichi Sawada; Makoto Hirokawa; Kazuo Oshimi; Koichi Sugimoto; Akira Matsuda; Masanao Teramura; Masamitsu Karasawa; Ayako Arai; Yuji Yonemura; Shinji Nakao; Akio Urabe; Mitsuhiro Omine; Keiya Ozawa
Journal:  Haematologica       Date:  2008-07-18       Impact factor: 9.941

9.  The pathophysiology of pure red cell aplasia: implications for therapy.

Authors:  R J Charles; K M Sabo; P G Kidd; J L Abkowitz
Journal:  Blood       Date:  1996-06-01       Impact factor: 22.113

10.  T-cell large granular lymphocyte leukemia: an Asian perspective.

Authors:  Yok-Lam Kwong; Wing-Yan Au; Anskar Y H Leung; Eric W C Tse
Journal:  Ann Hematol       Date:  2010-04       Impact factor: 3.673

View more
  2 in total

1.  Clinical characteristics and outcomes of 100 adult patients with pure red cell aplasia.

Authors:  Xuemei Wu; Lang Cheng; Xiaoqing Liu; Yu Sun; Bingzong Li; Guangsheng He; Jianyong Li
Journal:  Ann Hematol       Date:  2022-04-23       Impact factor: 3.673

2.  Induced complete remission faster in adult patients with acquired pure red cell aplasia by combining cyclosporine A with corticosteroids.

Authors:  Xuemei Wu; Yan Yang; Xingyu Lu; Hua Yin; Suli Wang; Shuai Wang; Ming Hong; Yu Zhu; Ruinan Lu; Chun Qiao; Yujie Wu; Guangsheng He; Jianyong Li
Journal:  Medicine (Baltimore)       Date:  2019-10       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.